Reported Saturday, Dr. Reddy's Breaks Ground As First Generic Semaglutide Injection Launcher In Canada, Expanding Global GLP-1 Therapy Access

Dr. Reddy's Laboratories Ltd. Sponsored ADR

RDY

0.00

The launch follows Dr. Reddy's receipt of the Notice of Compliance (NOC) from Health Canada on April 28th, 2026, marking the company's readiness to serve Canadian patients
Dr. Reddy's is the first company to receive Health Canada approval for generic Semaglutide Injection in Canada
Canada is the first G7 country to grant market authorization for generic Semaglutide Injection

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.